What type of study is this?

This is a In Vitro Study study.

December 8, 2025BloodOpen Access

An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals immune dysfunction and altered T-cell activation in relapsed high-risk multiple myeloma, suggesting therapy implications.

High-risk multiple myeloma shows significant immune dysfunction, with altered T-cell activation reducing efficacy of immunotherapy.
Notably, CD8a+/CD4+ T-cell ratios were elevated in high-risk patients, indicating a shift in T-cell composition affecting treatment response.
Our investigation included flow cytometry and scRNAseq analysis of bone marrow cells from chemotherapy-treated and untreated patients.
Findings highlight the need for innovative immunotherapeutic strategies in treating high-risk multiple myeloma, especially targeting T-cell function.

Stanojkovska et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals immune dysfunction and altered T-cell activation in relapsed high-risk multiple myeloma, suggesting therapy implications.

High-risk multiple myeloma shows significant immune dysfunction, with altered T-cell activation reducing efficacy of immunotherapy.
Notably, CD8a+/CD4+ T-cell ratios were elevated in high-risk patients, indicating a shift in T-cell composition affecting treatment response.
Our investigation included flow cytometry and scRNAseq analysis of bone marrow cells from chemotherapy-treated and untreated patients.
Findings highlight the need for innovative immunotherapeutic strategies in treating high-risk multiple myeloma, especially targeting T-cell function.

Stanojkovska et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark